https://orcid.org/0000-0002-3137-0886
References
- Natkunam Y, Goodlad JR, Chadburn A, et al. EBV-Positive B-Cell proliferations of varied malignant potential: 2015 SH/EAHP workshop report-part 1. Am J Clin Pathol. 2017;147(2):129–152.
- Natkunam Y, Gratzinger D, Chadburn A, et al. Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal? Blood. 2018;132(18):1871–1878.
- Münz C. Latency and lytic replication in Epstein-Barr virus-associated oncogenesis. Nat Rev Microbiol. 2019;17(11):691–700.
- Menter T, Juskevicius D, Alikian M, et al. Mutational landscape of B-cell post-transplant lymphoproliferative disorders. Br J Haematol. 2017;178(1):48–56.
- Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33.
- Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of lenalidomide in B-cell Non-Hodgkin lymphoma. J Clin Oncol. 2015;33(25):2803–2811.
- Kwong YL. Radiologic and molecular remission of follicular T cell lymphoma treated with lenalidomide. Ann Hematol. 2017;96(3):513–515.
- Chan TSY, Mak V, Kwong YL. Complete radiologic and molecular response of HIV-negative primary effusion lymphoma with short-course lenalidomide. Ann Hematol. 2017;96(7):1211–1213.
- Hwang YY, Au-Yeung R, Lau HP, et al. Complete response of age-related Epstein-Barr virus-associated polymorphic nodal lymphoproliferative disease of plasmacytic type to low-dose lenalidomide. Ann Hematol. 2018;97(2):363–366.
- Dojcinov SD, Venkataraman G, Raffeld M, et al. EBV positive mucocutaneous ulcer–a study of 26 cases associated with various sources of immunosuppression. Am J Surg Pathol. 2010;34(3):405–417.
- Zanelli M, Sanguedolce F, Palicelli A, et al. EBV-Driven Lymphoproliferative disorders and lymphomas of the gastrointestinal tract: a spectrum of entities with a common denominator (part 1). Cancers (Basel). 2021;13(18):4578.